PHARMACODYNAMIC MODELING OF THE ANALGESIC EFFECTS OF PIRITRAMIDE IN POSTOPERATIVE-PATIENTS

Citation
D. Kietzmann et al., PHARMACODYNAMIC MODELING OF THE ANALGESIC EFFECTS OF PIRITRAMIDE IN POSTOPERATIVE-PATIENTS, Acta anaesthesiologica Scandinavica, 41(7), 1997, pp. 888-894
Citations number
22
Categorie Soggetti
Anesthesiology
ISSN journal
00015172
Volume
41
Issue
7
Year of publication
1997
Pages
888 - 894
Database
ISI
SICI code
0001-5172(1997)41:7<888:PMOTAE>2.0.ZU;2-L
Abstract
Background: The concentration-effect relationship of piritramide, a sy nthetic opioid analgesic predominantly used for postoperative analgesi a and analgosedation, has not been reported so far. Methods: Twenty-fo ur patients of both genders aged 58.1 (11.7) yr (mean (SD)) received i nhalational anaesthesia for abdominal surgery. Postoperative pain was assessed with a visual analogue scale (VAS). Analgesia was provided wi th piritramide, infused at a rate of 7 mu g.kg(-1).min(-1) until analg esia was considered sufficient NAS<25) or up to a maximum dose of 0.2 mg/kg. The plasma concentrations of piritramide were determined by gas chromatography. An inhibitory fractional sigmoid E-max-model was used to describe the relation between effect site concentration and percei ved pain. Results: The equilibration half-life between plasma and effe ct site concentrations (T-1/2(k(eo))) was 16.8 min (median; range: 4.4 -41.6 min). The steady-state plasma concentration required to produce 50% of maximum analgesia (E-50) was 12.1 ng/ml (range: 2.9-29.8 ng/ml) and correlated with initial pain intensity. The slope factor gamma wa s 1.9 (range: 0.5-6.1) and increased with age. Clinically relevant res piratory depression did not occur Due to the relevant large equilibrat ion half-life of the effect compartment, the context-sensitive half-ti me of the effect site concentrations after short-time administration ( <2 h) clearly exceeded those of alfentanil, sufentanil, and fentanyl. Conclusions: The analgesic effect of piritramide was adequately descri bed by an inhibitory fractional E-max-model. in order to overcome the pronounced hysteresis, piritramide should initially be administered as an intravenous bolus of at least 5 mg.